Study shows good results for trabeculectomy with adjunctive ranibizumab

This prospective study randomized 10 patients with glaucoma to intravitreal ranibizumab 0.5 mg and topical mitomycin C (MMC) or MMC alone at time of trabeculectomy. Blebs were graded using the Moorfields Bleb Grading System. After six months both groups showed a successful lowering of IOP to between 5 and 22 mm Hg and a 30 percent decrease from baseline without use of postoperative hypotensive drops. However, the ranibizumab group exhibited more diffuse blebs with less vascularity. The authors note that this study has been expanded to include a longer follow-up, more patients in each study arm, and a third arm involving intravitreal ranibizumab therapy alone.